UniProt Accession Number of Target Protein: P41274

Alternative Name(s) of Target: CD137L; TNFSF9; 4-1BB ligand; 41BBL; CDw137L; homolog of mouse 4-1BB-L; receptor 4-1BB ligand; tumor necrosis factor (ligand) superfamily member 9; tumor necrosis factor (ligand) superfamily, member 9; tumor necrosis factor ligand 5A; Tumor necrosis factor ligand superfamily member 9.Immunogen: This antibody was raised by immunising LOU rats with soluble recombinant 4-1BBL:Fc fusion protein.

Specificity: This antibody is specific for 4-1BB ligand (also known as CD137 ligand), which is a member of the TNF superfamily and is a type II membrane protein. 4-1BB ligand is a co-stimulatory molecule that is expressed on antigen presenting cells (DCs, monocytes/macrophages, B cells) and is upregulated upon activation of these cells. Both of the 4-1BB ligand and its receptor, TNFRSF9/4-1BB, are involved in the antigen presentation process and in the generation of cytotoxic T cells. In direct ELISAs, no cross‑reactivity with recombinant human RELT is observed.

Application Notes: This antibody has been used in various FACS analyses, for instance, to show that CD27:CD70 and 4-1BB:4-1BBL interactions are needed for dendritic cell-driven accumulation of antitumor cytotoxic T lymphocytes following anti-CD40 mAb treatment (French et al, 2007), to examine the underlying mechanisms of the differential T cell costimulation dependence in viral infections (Welten et al, 2015), and to explore the therapeutic benefit of using combinations of syngeneic tumor vaccines that express immune modulators (Manrique-Rincón et al, 2017). This antibody has been used as a blocking antibody, together with anti-CD70, anti-CD30L and anti-OX40L antibodies, to evaluate OX40 ligand and CD70 in the promotion of CD4+ T cell responses (Kurche et al, 2010). Furthermore, this anti-4-1BBL antibody has been used alongside the anti-CD70, anti-CD27, anti-CD40 antibodies in a BCL1-bearing mouse model to evaluate the theurapeutic potency of various combined immmunotherapies against lymphoma (French et al, 2007).

Antibody first published in:French Ruth et al.Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.Blood. 2007 Jun 1;109(11):4810-5.PMID:17311995Note on publication:Describe the generation of this antibody and its subsequent use alongside with other antibodies to demonstrate that the eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.